– Deal combines TC BioPharm’s leading gamma delta T Cell capabilities with bluebird’s proven expertise in all stages of CAR T and gene therapy product development to discover and develop next-generation liquid and solid tumor product candidates –
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171207005574/en/
“Emerging research suggests that gamma delta T cells may constitute a
powerful platform for CAR T cell therapies,” said
Commenting on the partnership with bluebird bio, TCB’s chief executive -
“We believe our gamma delta T cell platform has broad therapeutic
potential,” added
“bluebird bio is leveraging its industry-leading toolbox of advanced
cell and gene therapy technologies to accelerate immuno-oncology targets
from concept to clinic,” said
Under the terms of the agreement, bluebird bio and TCB will collaborate to discover and develop CAR-engineered gamma delta T cells for cancer targets and indications. TCB is responsible for development of all targets through Phase 1/2, at which point bluebird has the exclusive option to assume sole responsibility for further clinical development and commercialization on a global basis.
Financial terms of the agreement include a
About bluebird bio, Inc.
With its lentiviral-based gene therapies, T cell immunotherapy expertise and gene editing capabilities, bluebird bio has built an integrated product platform with broad potential application to severe genetic diseases and cancer. bluebird bio’s gene therapy clinical programs include its Lenti-D™ product candidate, currently in a Phase 2/3 study, called the Starbeam Study, for the treatment of cerebral adrenoleukodystrophy, and its LentiGlobin® BB305 product candidate, currently in three clinical studies for the treatment of transfusion-dependent β-thalassemia, also known as β-thalassemia major, and severe sickle cell disease. bluebird bio’s oncology pipeline is built upon the company’s leadership in lentiviral gene delivery and T cell engineering, with a focus on developing novel T cell-based immunotherapies, including chimeric antigen receptor (CAR T) and T cell receptor (TCR) therapies. bluebird bio’s lead oncology programs, bb2121 and bb21217, are anti-BCMA CAR T programs partnered with Celgene. bb2121 and bb21217 are each currently being studied in Phase 1 trials for the treatment of relapsed/refractory multiple myeloma. bluebird bio also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies with the potential for use across the company’s pipeline.
bluebird bio has operations in Cambridge, Massachusetts, Seattle,
LentiGlobin and Lenti-D are trademarks of bluebird bio, Inc.
About TC BioPharm
Headquartered in
TCB has developed a novel gamma-delta CAR T platform (ImmuniCAR®) where T cells are supercharged using gene-therapy to target and kill specific cancer types. ImmuniCAR® represents a truly disruptive, step-changing approach to the treatment of a wide variety of cancers with potential to overcome many of the safety problems previously seen with conventional early-generation CAR T products. TCB is developing CAR T products against a range of cancer antigens with the potential to target both solid and blood tumors.
ImmuniCAR is a trademark of
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995, including
statements regarding the research, development and advancement of
bluebird bio’s product candidates and immuno-oncology research program,
including its own CAR T and TCR research programs and those shared with
TC BioPharm. Any forward-looking statements are based on management’s
current expectations of future events and are subject to a number of
risks and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include, but
are not limited to, the risk that the research programs for these
targets will be unsuccessful and not identify any viable product
candidates, the risk that our collaboration with TC BioPharm will not
continue or will not be successful, the risk of cessation or delay of
any planned clinical studies and/or our development of our product
candidates, and the risk that any one or more of our product candidates
will not be successfully developed and commercialized. For a discussion
of other risks and uncertainties, and other important factors, any of
which could cause our actual results to differ from those contained in
the forward-looking statements, see the section entitled “Risk Factors”
in our most recent Form 10-Q, as well as discussions of potential risks,
uncertainties, and other important factors in our subsequent filings
with the
View source version on businesswire.com: http://www.businesswire.com/news/home/20171207005574/en/
Source: bluebird bio, Inc.
bluebird bio
Investors & Media
Elizabeth Pingpank,
617-914-8736
epingpank@bluebirdbio.com
or
TC
BioPharm
Investors & Media
Artin Moussavi,
+44(0)141-433-7557
press@tcbiopharm.com